AR-15512, a transient receptor potential melastatin 8 agonist, demonstrated significant improvement of dry eye disease signs, symptoms and related quality of life in a phase 2b study.
The potential benefits of targeting neuronal pathways as an alternative treatment option for dry eye were demonstrated in a previous phase 1/2a study that showed AR-15512 at 0.0014% concentration was safe and well tolerated and resulted in improved tear production, tear stability and dry eye disease (DED) symptoms.
The phase 2b randomized, vehicle-controlled, multicenter clinical study was designed to better